A still-undiscovered European-based, development-stage biotech company by the name of Ventana Biotech (VNTA) has finally zeroed in on a potential solution:
an anti-obesity chewing gum that early indications show reduces appetite by 15% to 25%. And here's the thing, because it doesn't rely upon a pharmaceutical chemical, it doesn't pose any of their unwanted side effects. It relies instead upon a powerful human hormone that reduces over eating by tricking the brain into thinking "the stomach is full." The principle is simple - Ventana Biotech"s gum will use the same an all-natural hormone that the human body produces after eating to signal the brain and suppresses the urge to eat. By chewing the gum before a meal or any time there are food cravings, the hormone acts to control hunger.
| A hormone that literally flips off the hunger switch. |
And Ventana Biotech (VNTA) is developing a way to incorporate nature's highly-effective appetite controller in an anti-obesity chewing gum that would revolutionize the $35 billion obesity market! A weight-conscious consumer simply chews the gum a half hour or so before eating, or anytime it's needed to fight off hunger.
The company's plan is to patent the gum in the USA. the United Kingdom, India, China, Canada France and Scandinavia, where the number of obese people surpasses the number of starving people.
This is a huge market and when big pharma gets wind of this breakthrough, I believe they'll be after little Ventana Biotech's Intellectual Property with a $215 billion war chest. That's right, big pharma is desperate to acquire successful patents and the likes of GlaxoSmithKline, Novo, and AstraZeneca will be lining up to pay licensing fees that could be...
 |  | |
| Worth an estimated $1.5 - $1.7 billion in cash flow! | ||
 |  | |
Ventana Biotech's planned anti-hunger chewing gum has many parallels to the development of the widely used anti-smoking gums. According to IRI Sales Data, the latest wrinkle, a new mint flavored anti-smoking gum racked up an astonishing $300 million in sales for the twelve months ending in Sept 2008. Nicorette gum is a huge profit maker for GlaxoSmithKline!
Shares of European-based Ventana Biotech (VNTA) only began trading on the U.S. market a few weeks ago and right now you can still buy in at under 60-cents a share. But this dynamo of a company has a very savvy management and given the potential stakes, and the potential for a big pharma buyout, I would not be at all surprised to see its price explode. Yes, biotech can be volatile, but that's exactly the reason to buy shares of Ventana (VNTA) now before it's discovered.
No comments:
Post a Comment